Expand ACTU Menu
ACTU MENU

ACTU Latest Press Releases

-- January 12, 2026 --

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 Globe Newswire 8:45 AM

-- January 6, 2026 --

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers Globe Newswire 8:45 AM

-- December 18, 2025 --

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 Globe Newswire 8:45 AM

-- December 15, 2025 --

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma Globe Newswire 8:45 AM

-- October 30, 2025 --

Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP) AB Digital Inc 2:49 PM

-- September 22, 2025 --

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months Globe Newswire 8:45 AM

-- September 11, 2025 --

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option Globe Newswire 4:01 PM

-- September 10, 2025 --

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock Globe Newswire 8:31 AM

-- September 9, 2025 --

Actuate Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:07 PM
Market Data Delayed 15 Minutes